Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, a… Read more
Divi's Laboratories Limited (DIVISLAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.107x
Based on the latest financial reports, Divi's Laboratories Limited (DIVISLAB) has a cash flow conversion efficiency ratio of 0.107x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹16.45 Billion) by net assets (₹154.13 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Divi's Laboratories Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Divi's Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Divi's Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Divi's Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qiagen NV
NYSE:QGEN
|
0.050x |
|
ACS Actividades de Construcción y Servicios S.A
PINK:ACSAF
|
0.330x |
|
Manhattan Associates Inc
NASDAQ:MANH
|
0.467x |
|
Capcom Co. Ltd
PINK:CCOEF
|
-0.045x |
|
InCapta Inc
PINK:INCT
|
-0.076x |
|
Hindustan Aeronautics Limited
NSE:HAL
|
0.216x |
|
Inspur Electronic Info Industr
SHE:000977
|
-0.327x |
|
Wayfair Inc
NYSE:W
|
-0.056x |
Annual Cash Flow Conversion Efficiency for Divi's Laboratories Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Divi's Laboratories Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹149.69 Billion | ₹19.46 Billion | 0.130x | +39.91% |
| 2024-03-31 | ₹135.71 Billion | ₹12.61 Billion | 0.093x | -51.77% |
| 2023-03-31 | ₹127.67 Billion | ₹24.60 Billion | 0.193x | +18.19% |
| 2022-03-31 | ₹117.28 Billion | ₹19.12 Billion | 0.163x | -22.18% |
| 2021-03-31 | ₹92.95 Billion | ₹19.47 Billion | 0.209x | +25.93% |
| 2020-03-31 | ₹73.10 Billion | ₹12.16 Billion | 0.166x | +21.27% |
| 2019-03-31 | ₹69.57 Billion | ₹9.54 Billion | 0.137x | +4.75% |
| 2018-03-31 | ₹59.25 Billion | ₹7.76 Billion | 0.131x | -38.96% |
| 2017-03-31 | ₹53.57 Billion | ₹11.49 Billion | 0.215x | -11.26% |
| 2016-03-31 | ₹42.93 Billion | ₹10.38 Billion | 0.242x | +2.25% |
| 2015-03-31 | ₹34.95 Billion | ₹8.26 Billion | 0.236x | +25.83% |
| 2014-03-31 | ₹29.63 Billion | ₹5.57 Billion | 0.188x | -2.12% |
| 2013-03-31 | ₹25.01 Billion | ₹4.80 Billion | 0.192x | +20.92% |
| 2012-03-31 | ₹21.32 Billion | ₹3.38 Billion | 0.159x | -12.62% |
| 2011-03-31 | ₹17.97 Billion | ₹3.27 Billion | 0.182x | -25.34% |
| 2010-03-31 | ₹15.18 Billion | ₹3.69 Billion | 0.243x | +0.31% |
| 2009-03-31 | ₹12.41 Billion | ₹3.01 Billion | 0.243x | -28.55% |
| 2008-03-31 | ₹8.61 Billion | ₹2.92 Billion | 0.340x | -0.09% |
| 2007-03-31 | ₹5.35 Billion | ₹1.82 Billion | 0.340x | +136.67% |
| 2006-03-31 | ₹3.40 Billion | ₹488.03 Million | 0.144x | +17.14% |
| 2005-03-31 | ₹2.84 Billion | ₹347.70 Million | 0.123x | -- |